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PURPOSE: To determine the nature of hyaline membranes in different manifestations of diffuse alveolar damage, [pulmonary
and extrapulmonary acute respiratory distress syndrome], and idiopathic [acute interstitial pneumonia].
MATERIALS AND METHODS: Pulmonary specimens were obtained from 17 patients with acute respiratory distress syndrome
and 9 patients with acute interstitial pneumonia. They were separated into 3 different groups: (a) pulmonary diffuse alveolar damage
(pDAD) (n = 8), consisting only of pneumonia cases; (b) extrapulmonary diffuse alveolar damage (expDAI) (n = 9), consisting of
sepsis and septic shock cases; and (c) idiopathic diffuse alveolar damage (iDAD) (n = 9), consisting of idiopathic cases (acute
interstitial pneumonia). Hyaline membranes, the hallmark of the diffuse alveolar damage histological pattern, were examined using
various kinds of antibodies. The antibodies used were against surfactant apoprotein-A (SP-A), cytokeratin 7 (CK7), cytokeratin 8
(CK8), alpha smooth muscle actin (α-SMA), cytokeratin AE1/AE3 (AE1/AE3), and factor VIII-related antigen (factor VIII).
RESULTS: Pulmonary diffuse alveolar damage showed the largest quantity of hyaline membranes (12.65% ± 3.24%), while
extrapulmonary diffuse alveolar damage (9.52% ± 3.64%) and idiopathic diffuse alveolar damage (7.34% ± 2.11%) showed intermediate
and lower amounts, respectively, with the difference being statistically significant between pulmonary and idiopathic diffuse alveolar
damage (P < 0.05). No significant difference was found for hyaline membranes Sp-A immunostaining among pulmonary (15.36% ±
3.12%), extrapulmonary (16.12% ± 4.58%), and idiopathic (13.74 ± 4.20%) diffuse alveolar damage groups. Regarding factor VIII,
we found that idiopathic diffuse alveolar damage presented larger amounts of immunostained hyaline membranes (14.12% ± 6.25%)
than extrapulmonary diffuse alveolar damage (3.93% ± 2.86%), with this difference being statistically significant (P < 0.001). Equally
significant was the difference for progressive decrease of cytokeratin AE1/AE3 immunostaining in hyaline membranes present in the
extrapulmonary diffuse alveolar damage (5.42% ± 2.80%) and idiopathic diffuse alveolar damage (0.47% ± 0.81%) groups (P <
0.001). None of the groups stained for cytokeratin CK-7, CK-8, vimentin, or α anti-smooth muscle actin.
CONCLUSIONS: This study showed that only the epithelial/endothelial components (SP-A, factor VIII, and AE1/AE3) of the
alveolar/capillary barrier are present in hyaline membranes formation in the 3 groups of patients with diffuse alveolar damage.
The significant difference in the expression of factor VIII-related antigen and cytokeratin AE1/AE3 in the expDA versus iDAD
groups as well as the significant difference in the amount of hyaline membranes present in the pDAD versus iDAD groups are
suggestive of a local and specific lesion with different pathways (direct, indirect, or idiopathic), depending on the type of diffuse
alveolar damage.
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INTRODUCTION
The pathogenesis of acute respiratory distress syndrome
(ARDS) leading to increased alveolar capillary permeability
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and diffuse inflammatory infiltration, manifested clinically
as refractory hypoxemia in association with decreased lung
compliance and radiographically as bilateral pulmonary
infiltrates, is not well understood.
Two pathways are supposed to be involved in ARDS
pathogenesis: (a) the pulmonary or direct effects of an
inhalatory insult on lung cells and (b) the extrapulmonary
or indirect result of an acute systemic inflammatory re-
sponse; however, the causes of ARDS still pose a challenge.
In this regard, many have studied the differences be-
tween pulmonary ARDS (pARDS) and extrapulmonary
ARDS (expARDS) in a quest for what might be related
to the dramatic mechanisms of hypoxemia. In 1998,
Gattinoni et al1 suggested that patients suffering direct
pulmonary insults show lower compliance and have al-
veolar units that are less susceptible to recruitment by
mechanical ventilation than do those with extrapulmonary
initiating processes.
In 1999, Pelosi et al2 analyzed chest radiographs by us-
ing appropriate scores and found that patients with direct
lung injury presented increased patchy densities and edema
scores when compared to patients with indirect lung injury,
whereas the amount of hazy and extensive densities were
similar in both groups. Goodman et al3 analyzed CT scans
and found that pARDS tends to be asymmetric, with a mix
of consolidation and ground-glass opacification, whereas
expARDS has a predominantly symmetric ground-glass
opacification. Similar findings have been reported in which
less recruitable lung regions in patients with pneumonia are
described.4,5
Because the lung injury in ARDS results in diffuse al-
veolar damage (DAD), a group of morphologic parameters
have been targeted as potentially useful by Hoelz et al;6
among these, hyaline membranes have been investigated.
Hyaline membrane (HM) was first described by Hamman
and Rich in acute interstitial fibrosis7 and since then it has
been seen as an acute histological parameter occurring in
a progressive, fatal, and distinct form of interstitial pneu-
monia8,9 classified by the American Thoracic Society/Eu-
ropean Respiratory Society (ATS/ERS)10 as acute intersti-
tial pneumonia.
Immunostaining of HM is heterogeneous, suggesting
that it may be formed through different mechanisms in vari-
ous types of diffuse interstitial pneumonia.11 In order to
validate the importance of HM and explore the quantita-
tive relationship between this factor and parenchymal
changes in diffuse alveolar damage, as well as to charac-
terize the immunostaining features of HM, we studied HM
in lungs of patients with different manifestations of DAD
[pulmonary and extrapulmonary (ARDS) and idiopathic
acute interstitial pneumonia (AIP)].
MATERIALS AND METHODS
Patients and Lung Tissue
Pulmonary specimens were obtained from 26 patients
with DAD by surgical lung biopsy and necropsy from 1998
to 2003. All of the patients exhibited clinical, radiologi-
cal, and physiological alterations consistent with ARDS
according to the 1992 American-European Consensus12 and
had received the definitive pathological diagnosis of dif-
fuse alveolar damage (DAD). Patients with ARDS were
separated into 3 groups: (a) pulmonary DAD (pDAD) (n =
8), consisting only of pneumonias cases; (b) extra-
pulmonary DAD (expDAD) (n = 9), consisting of sepsis
and septic shock cases; and (c) idiopathic DAD (iDAD) (n
= 9), consisting of idiopathic cases (or acute interstitial
pneumonia), according to the criteria outlined in the Ameri-
can Thoracic Society/European Respiratory Society Inter-
national Multidisciplinary Consensus Classification of the
Idiopathic Interstitial Pneumonias.10 Pulmonary tissues were
fixed in 10% phosphate-buffered formalin solution, cut into
slices, embedded in paraffin, and sectioned at a thickness
of 4 µm for histological evaluation with hematoxylin and
eosin (H&E). From the H&E sections of each case, repre-
sentative sections containing HM were chosen for immu-
nohistochemical analysis.
Hyaline membrane evaluation
Hyaline membranes were evaluated by immunohisto-
chemical staining using the avidin-biotin immuno-
peroxidase complex technique. The antibodies used were
antisurfactant apoprotein-A (SP-A) (Clone PE10; Dako;
1:800 dilution), which is used to differentiate type II
pneumocytes and Clara cells; anticytokeratin 7 (CK7)
(Clone OV-TL 12/30; Dako; 1:100 dilution), used to dif-
ferentiate type I and II pneumocytes and bronchial epithe-
lial cells; anticytokeratin 8 (CK8) (Dako; 1:200 dilution),
used to differentiate simple epithelia; antivimentin (Dako;
1:800 dilution), used to differentiate mesenchymal cells;
anti-alpha smooth muscle actin (α-SMA) (Novocastra;
1:500 dilution), anticytokeratin AE1/AE3 (AE1/AE3)
(Dako; 1:100 dilution), used to differentiate keratinized
epidermis, simple epithelia, and squamous stratified epi-
thelia of internal organs; and antifactor VIII-related anti-
gen (anti-Factor VIII) (Dako; 1:400 dilution), used to dif-
ferentiate endothelial cells. Positive and negative controls
were stained in parallel, and staining processes were per-
formed according to the manufacturer’s instructions.
To quantify the immunostaining of HM, we counted 500
lines (or 10 fields) per case at X400 magnification in each
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case, using a conventional stereological method. Briefly,
this method is a line-counting procedure that consists of a
reticulated eyepiece made of 100 points and 50 lines, each
one with a length of 25 mm at a magnification of X400,
coupled to a conventional light microscope. Counting was
performed by using a cascade progressive sampling ap-
proach. The error in this procedure is estimated as being
lower than 5%.13 The numbers of positively and negatively
stained HM were averaged to obtain a final result, ex-
pressed as a percentage.
We considered negative cases of HM immunostaining
to be those with a lower staining level than controls or cases
with a staining level resulting in less than 10 lines overly-
ing HM.
Statistical analysis
For the quantification of HM, we used the 1-way
ANOVA procedure for analysis of variance of immunohis-
tochemical stains and their distributions, as well as for
analyzing the tissue and air density in the 3 groups (pDAD,
expDAD, and iDAD) Differences among the means were
compared a priori by Levene’s test for homogeneity of vari-
ance and then by the Dunnett T3 multiple comparisons post
hoc tests. The level of significance was set at 0.05. The
data were analyzed using the SPSS for Windows program,
release 11.0.13
RESULTS
Histopathological evaluation
Figure 1 shows the histological features of HM in
pDAD, expDAD, and iDAD.
Hyaline membrane was the major histopathological al-
teration in all 26 cases studied. It was observed as an eosi-
nophilic material lining alveolar surfaces, presenting in dif-
ferent ways depending on the group studied. For instance,
HM appeared as a continuous thin layer on the alveolar sur-
face in expDAD or discontinuous and fragmented in iDAD
and pDAD. Type I and II pneumocytes (PI and PII respec-
tively), macrophages, blood cells, and edema, bordering or
mixed with HM, were also present.
As shown in Figure 2 and Table 1, pDAD showed
the largest quantity of HM (12.65% ± 3.24%), while
epDAD (9.52% ± 3.64%) and iDAD (7.34% ± 2.11%)
Table 1 - Results of the statistical analysis of the quantitation of hyaline membrane (HM) and the 3 antigens that showed
immunohistochemical positivity among the 3 groups of patients with DAD (mean + SD)
Types of Diffuse Alveolar Damage
Variables Extrapulmonary DAD Pulmonary DAD Idiopathic DAD P
HM 9.52 ± 3.64 12.65 ± 3.24* 7.34 ± 2.11* 0.01
SP-A 16.12 ± 4.58 15.36 ± 3.12 13.74 ± 4.20 0.50
Factor VIII 3.93 ± 2.86* 7.49 ± 7.30 14.12 ± 6.25* 0.001
AE1/AE3 5.42 ± 2.80* 2.15 ± 4.41 0.47 ± 0.81* 0.001
*Variables with P < 0.05.
Figure 1 - Hyaline membrane (HM) (arrows) in 3 groups of diffuse alveolar
damage (DAD)—extrapulmonary DAD, pulmonary DAD, and idiopathic
DAD—is eosinophilic material lining alveolar surfaces that is presented in
different ways depending on the group studied. Hyaline membrane appeared
as a thick layer near basal membrane (in all groups), as a variable thin layer
on the alveolar surface (in extrapulmonary DAD), and as interstitial fragments
in cases in which there was less alveolar space (especially in idiopathic DAD
and pulmonary DAD). Hyaline membrane of all 3 groups reacted with
antibodies to surfactant apoprotein-A (SP-A). The extrapulmonary DAD
group reacted with anti-Factor VIII in a few cases and was the only group
that stained for AE1/AE3. The pulmonary DAD group had an intermediate
stain level for factor VIII, but did not react with anti-AE1/AE3. All the HM
of the idiopathic DAD group stained for Factor VIII and also did not react
with anti-AE1/AE3
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showed intermediate and lower amounts, respectively, with
this difference being statistically significant between pul-
monary and idiopathic DAD (P < 0.05).
Immunohistochemistry
The results of the HM immunostaining quantitation are
shown in Figure 2 and Table 1. No statistical differences
were found for HM Sp-A immunostaining among pulmo-
nary (15.36% ± 3.12%), extrapulmonary (16.12% ±
4.58%), and idiopathic (13.74% ± 4.20%) DAD groups.
Regarding factor VIII, we found that iDAD presented larger
amounts of immunostained HM (14.12% ± 6.25%) than
expDAD (3.93 ± 2.86%), with this difference being statis-
tically significant (P < 0.001). Equally significant was the
difference for the progressive decrease of cytokeratin AE1/
AE3 immunostaining in HM present in the expDAD (5.42%
± 2.80%) versus iDAD (0.47% ± 0.81%) groups (P <
0.001).
Immunostaining for cytokeratin CK-7, CK-8, vimentin,
and a-SMA HM was negative in the pDAD, epDAD, and
iDAD groups.
DISCUSSION
Hyaline membrane is the histological hallmark of
ARDS and AIP and results from acute inflammatory proc-
esses in interstitial and alveolar compartments.15 The com-
position of HM is not completely known, and its
pathogenesis is still controversial.10 In this study, we inves-
tigated the immunohistochemical features of HM in 3
groups of patients who presented different manifestations
of DAD [pulmonary ARDS, extra pulmonary ARDS, and
idiopathic DAD (AIP)].
Our findings show that the surfactant apoprotein-A (SP-
A), a marker of type II pneumocytes, is strongly positive
in the HM of all groups. This staining also allowed a bet-
ter identification of the HM pycnotic nuclei, which were
probably derived from injured type II pneumocytes.
When factor VIII was studied through the staining of en-
dothelial cytoplasmic proteins, we observed strongly posi-
tive staining in iDAD, which was also coincident with the
intensity of staining for SP-A, showing that HM in this group
results from the simultaneous destruction of type II
pneumocytes and endothelium. Pulmonary DAD, a group
with intermediate factor VIII expression, was found only in
pneumonia cases. These cases are usually characterized by
intense inflammatory process with cytokines (TNF-± and
interleucin-1) and complement (C5-a and C5b-9) activation,
resulting in overexpression of macrophages and neutrophils
with substantial superoxide production and endothelial de-
struction.16,17 On the other hand, the lower amount of factor
VIII expression in the expDAD group probably coincides
with minor endothelium injury. In our study, this group was
composed of only sepsis or septic shock cases, usually char-
acterized by systemic (but not local) inflammatory injury,
with vascular dilatation and less capillary exchange. This
finding had been previously shown by Grandel and
Grimminger,18 who demonstrated that endothelial alteration
might occur by cell dysfunction (including type I and II
pneumocytes) without vascular destruction.
Cytokeratin AE1/AE3 staining is positive in almost all
epithelia because it reacts with keratinized epithelium, strati-
fied desquamative epithelium of internal organs, proliferat-
ing keratinocytes, and simple epithelium. In our study,
cytokeratin AE1/AE3 was highly positive in expDAD (sep-
sis or septic shock cases), indicating the occurrence of epi-
thelial cells, whose integrity is necessary for adequate air
exchange. In contrast, the lower quantity of cytokeratin AE1/
AE3 found in pulmonary and idiopathic DAD suggests mini-
mal injury to epithelial cells. In addition, our study showed
that other epithelial markers, such as CK-7 and CK-8, were
not expressed in the HM. Cytokeratin 7, an intermediated
filament of glandular epithelium protein, is usually present
in type I and II pneumocytes, whereas CK-8 is present in
simple epithelium such as ductal carcinomas of the breast
and is usually present at minimal amounts in the alveolar
epithelium. These findings suggest that the alveolar epithe-
lium may have a small role in HM pathogenesis, because
among the 3 markers for epithelium used (CK-7, CK-8, and
AE1/AE3), AE1/AE3 was the only one that showed posi-
tive immunostaining in the expDAD group.
Figure 2 - Graphic illustration and quantitative analysis of hyaline membrane
(HM) under hematoxylin & eosin staining and immunostained for surfactant
apoprotein-A (SP-A), Factor VIII (F-VIII), and cytokeratin AE1/AE3 (AE1/
AE3) in extrapulmonary DAD, pulmonary DAD, and idiopathic DAD. The
1-way ANOVA procedure was used for analysis of variance of
immunohistochemical stains and their distributions, and for the quantification
of HM
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The interstitial markers used in this study such as
vimentin, specific for mesenchymal cells, and anti-α
smooth muscle α actin, specific for this kind of muscle,
were all negative for immunostaining, showing that HM
usually does not contain mesenchymal components.
In conclusion, this study shows that only the epithelial/
endothelial components (SP-A, factor VIII, and AE1/AE3)
of the alveolar/capillary barrier are present in HM forma-
tion in the 3 groups of patients with DAD. The significant
difference in the expression of factor VIII-related antigen
and cytokeratin AE1/AE3 in the expDAD versus iDAD
groups as well as the significant difference in the amount
of HM present in the pDAD versus iDAD groups are sug-
gestive of a local and specific lesion with different path-
ways (direct, indirect, or idiopathic), depending on the type
of the DAD.
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RESUMO
Peres e Serra A, Parra ER, Eher E, Capelozzi VL.
Imunomarcação não homogênea das membranas hialinas
na sindrome da angustia respiratório do adulto pulmonar,
extrapulmonar e idiopática. CLINICS. 2006;61(6):497-502.
OBJETIVO: Determinar a natureza da membrana hialina
nas diferentes manifestações do dano alveolar difuso
[pulmonar e extrapulmonar síndrome do desconforto
respiratório] e idiopático [pneumonia intersticial aguda].
MATERIAIS E MÉTODOS: Espécimes pulmonares
foram obtidos de 17 pacientes com SDRA e 9 pacientes
com pneumonia intersticial aguda e separados em três
diferentes grupos: (a) dano alveolar difuso pulmonar
(DADp) (n=8) constituído por casos de pneumonia, (b)
dano alveolar difuso extrapulmonar (DADexp) (n=9)
constituído por casos de sepse e choque séptico e (c) dano
alveolar difuso idiopático (DADi) (n=9) constituído por
casos idopáticos (ou pneumonia intersticial aguda). As
características das membranas hialinas do padrão
histológico de dano alveolar difuso foram examinadas
usando vários tipos de anticorpos. Os anticorpos usados
foram surfactante apoproteina A (SP-A), anti-citokeratina
7 (CK7), citokeratina 8 (CK8), alfa actina de músculo liso
(a-SMA), citokeratina AE1/AE3 (AE1/AE3) e antígeno
relacionado ao fator VIII (Fator VIII).
RESULTADOS: Observaram-se aumentos maiores da
quantidade de membrana hialina no dano alveolar difuso
pulmonar (12.65 ± 3.24%), intermediários no dano alveo-
lar difuso extrapulmonar (9.52 ± 3.64%) e baixos no dano
alveolar difuso idiopático (7.34 ± 2.11%) respectivamente,
esta diferencia foi estatística significante entre o dano al-
veolar difuso pulmonar e o dano alveolar difuso idiopático
(p<0.05). Não se encontrou significância estatística para a
quantidade de imunomarcação de Sp-A nos grupos de dano
alveolar difuso pulmonar (15.36 ± 3.12%), extrapulmonar
(16.12 ± 4.58%) e idiopático (13.74 ± 4.20%). Com relação
ao Fator VIII, nós encontramos maiores aumentos da
imunomarcação da membrana hialina no grupo dano alveo-
lar difuso idiopático (14.12 ± 6.25%) do que no dano al-
veolar difuso extrapulmonar (3.93 ± 2.86%), com
significância estatística (p<0.001). Da mesma forma houve
um aumento progressivo da imunomarcação da membrana
hialina com citokeratina AE1/AE3 nos grupos de dano al-
veolar difuso extrapulmonar (5.42 ± 2.80%) e dano alveo-
lar difuso idiopático (0.47 ± 0.81%) (p<0.001). Nenhuns
dos grupos marcou para as citokeratina CK-7, CK-8 ou para
a vimentina ou actina de músculo liso.
CONCLUSÕES: Este estudo só mostra os componentes
epitelio/endotelio (SP-A, Fator VIII e AE1/AE) da barreira
alvéolo/capilar que estão presentes na formação da mem-
brana hialina nos três diferentes grupos, sugerindo que as
diferenças na sua patogênese dependem da via do ferimento
(direto, indireto, ou idiopático); que dependem da causa do
dano alveolar difuso. As diferenças na expressão do
antígeno relacionado ao Fator VIII e nas citoqueratinas
AE1/AE3 no grupo DADexp versus DADi, bem como as
diferenças entre HM presente no grupo DADp versus DADi
sugerem a ocorrência de lesões específicas com vias
diferentes (direta, indireta ou idiopática) dependentes do
tipo de DAD.
UNITERMOS: Síndrome do desconforto respiratório
agudo. Pneumonia intersticial aguda. Dano alveolar difuso.
Membrana hialina. Imuno-histoquímica.
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